{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:35:07Z","timestamp":1790976907835,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Lyall Watt\u2019s Mesothelioma"},{"name":"Australian Postgraduate"},{"name":"Ontario Institute for Cancer Research"},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jtho.2017.02.013","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T03:50:19Z","timestamp":1488340219000},"page":"850-859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma"],"prefix":"10.1016","volume":"12","author":[{"given":"Bibhusal","family":"Thapa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xihui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzena","family":"Walkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Murone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaka","family":"Ameratunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khashyar","family":"Asadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Deb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Arthur","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Neil","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2017.02.013_bib1","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.02.013_bib2","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1080\/14737140.2016.1244008","article-title":"Targeting the vasculature: anti-angiogenesis agents for malignant mesothelioma","volume":"16","author":"Chia","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jtho.2017.02.013_bib3","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.02.013_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety\u00a0of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabr\u00f2","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"suppl","key":"10.1016\/j.jtho.2017.02.013_bib5","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2016.34.15_suppl.8503","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression","volume":"34","author":"Hassan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.02.013_bib6","series-title":"Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18\u201322","first-page":"CT103","article-title":"Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-028","author":"Alley","year":"2015"},{"key":"10.1016\/j.jtho.2017.02.013_bib7","doi-asserted-by":"crossref","DOI":"10.1080\/14737140.2016.1241149","article-title":"Immunotherapy for mesothelioma: reality check","author":"Thapa","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"issue":"suppl","key":"10.1016\/j.jtho.2017.02.013_bib8","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1200\/JCO.2016.34.15_suppl.8502","article-title":"Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): results from the global, double-blind, placebo-controlled DETERMINE study","volume":"34","author":"Kindler","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.02.013_bib9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2017.02.013_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jtho.2017.02.013_bib11","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","author":"Snyder","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.02.013_bib12","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen\u2013specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2017.02.013_bib13","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2017.02.013_bib14","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 Expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.02.013_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2017.02.013_bib16","doi-asserted-by":"crossref","first-page":"e0153954","DOI":"10.1371\/journal.pone.0153954","article-title":"PD-L1 and tumor infiltrating lymphocytes as prognostic markers in resected NSCLC","volume":"11","author":"Ameratunga","year":"2016","journal-title":"PLoS One"},{"issue":"suppl 1","key":"10.1016\/j.jtho.2017.02.013_bib17","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1746-1596-9-S1-S7","article-title":"Automated image analysis in the study of lymphocyte subpopulation in eosinophilic oesophagitis","volume":"9","author":"Garcia-Rojo","year":"2014","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.jtho.2017.02.013_bib18","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.02.013_bib19","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.02.013_bib20","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S1470-2045(14)71021-6","article-title":"Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study","volume":"15","author":"Lalonde","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.02.013_bib21","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1101\/gr.135350.111","article-title":"GENCODE: the reference human genome annotation for the ENCODE project","author":"Harrow","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.jtho.2017.02.013_bib22","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol"},{"key":"10.1016\/j.jtho.2017.02.013_bib23","first-page":"357","article-title":"Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway","volume":"7","author":"Momtaz","year":"2014","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.jtho.2017.02.013_bib24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1517\/14712598.2013.770836","article-title":"Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy","volume":"13","author":"Hamid","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jtho.2017.02.013_bib25","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.02.013_bib26","first-page":"1","article-title":"Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of\u00a0pancreatic adenocarcinoma tissue","volume":"1","author":"Bigelow","year":"2013","journal-title":"J\u00a0Vis Exp"},{"key":"10.1016\/j.jtho.2017.02.013_bib27","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jtho.2017.02.013_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2288-10-20","article-title":"Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer","volume":"10","author":"Bellera","year":"2010","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jtho.2017.02.013_bib29","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.jtho.2017.02.013_bib30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2017.02.013_bib31","first-page":"232","article-title":"The role of key genes and pathways involved in the tumorigenesis of\u00a0malignant mesothelioma","volume":"1845","author":"De Assis","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jtho.2017.02.013_bib32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrg2593","article-title":"Mechanisms of change in gene copy number","volume":"10","author":"Hastings","year":"2009","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jtho.2017.02.013_bib33","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.1097\/MD.0000000000000515","article-title":"Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) expression in epithelial-originated cancer: a meta-analysis","volume":"94","author":"Zhang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jtho.2017.02.013_bib34","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1158\/1078-0432.CCR-14-1905","article-title":"Stromal CD8+ T-cell density\u2014a promising supplement to TNM staging in\u00a0non-small cell lung cancer","volume":"21","author":"Donnem","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.02.013_bib35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/PAT.0b013e328342016c","article-title":"Validation of tissue microarray technology in malignant pleural mesothelioma","volume":"43","author":"Kao","year":"2011","journal-title":"Pathology"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086417301247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086417301247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T05:52:50Z","timestamp":1568872370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086417301247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1556086417301247"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2017.02.013","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2017.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}